Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Insights into Ebola Virus VP35 and VP24 Interferon inhibitory functions and their initial exploitation as drug targets

Fanunza E, Frau A, Corona A, Tramontano E.

Infect Disord Drug Targets. 2018 Nov 23. doi: 10.2174/1871526519666181123145540. [Epub ahead of print]

PMID:
30468131
2.

Identification of Myricetin as an Ebola Virus VP35-Double-Stranded RNA Interaction Inhibitor through a Novel Fluorescence-Based Assay.

Daino GL, Frau A, Sanna C, Rigano D, Distinto S, Madau V, Esposito F, Fanunza E, Bianco G, Taglialatela-Scafati O, Zinzula L, Maccioni E, Corona A, Tramontano E.

Biochemistry. 2018 Nov 6;57(44):6367-6378. doi: 10.1021/acs.biochem.8b00892. Epub 2018 Oct 22.

PMID:
30298725
3.

Development and Validation of a Novel Dual Luciferase Reporter Gene Assay to Quantify Ebola Virus VP24 Inhibition of IFN Signaling.

Fanunza E, Frau A, Sgarbanti M, Orsatti R, Corona A, Tramontano E.

Viruses. 2018 Feb 24;10(2). pii: E98. doi: 10.3390/v10020098.

4.

A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs.

Abner E, Stoszko M, Zeng L, Chen HC, Izquierdo-Bouldstridge A, Konuma T, Zorita E, Fanunza E, Zhang Q, Mahmoudi T, Zhou MM, Filion GJ, Jordan A.

J Virol. 2018 Apr 27;92(10). pii: e02056-17. doi: 10.1128/JVI.02056-17. Print 2018 May 15.

Supplemental Content

Loading ...
Support Center